A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults With Fragile X Syndrome - RECONNECT
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Cannabidiol (Primary)
- Indications Fragile X syndrome
- Focus Registrational; Therapeutic Use
- Acronyms RECONNECT
- Sponsors Zynerba Pharmaceuticals
- 24 Jun 2024 Planned number of patients changed from 204 to 250.
- 06 May 2024 Planned End Date changed from 1 Mar 2024 to 1 May 2025.
- 06 May 2024 Planned primary completion date changed from 1 Mar 2024 to 1 May 2025.